Our Partners > Diamond Sponsors 2020



DIAMOND SPONSORS

At Adamas, we are passionate about improving lives and are driven by an important purpose - to make everyday life significantly better for people affected by neurological diseases. We are a fully integrated company focused on growing a portfolio of therapies that address a range of neurological diseases and reduce their burden on patients, caregivers, and society. Please visit https://adamas-unitywalk.com/.

 

Challenging Convention, Changing Lives

The Amneal team brings people and passion together to support our mission of making healthy possible for individuals affected by conditions like Parkinson’s disease. We believe every idea, every experience, and every detail can make a difference. That’s why we connect our passionate people to partnerships with patients, care partners, healthcare providers, and advocacy organizations.

We believe we can make a difference in the Parkinson’s community not just by bringing medicines to market, but by actively engaging with patients and care partners to understand the journey, unmet needs, opportunities to provide support—and to ensure their voice is reflected in everything we do.

Amneal also supports leading patient advocacy organizations across the U.S., including Davis Phinney Foundation, PMD Alliance, Michael J. Fox Foundation, Parkinson’s Foundation, and American Parkinson Disease Association. We provide valuable resources that help raise awareness and funding for important education and research.

We are Amneal. And we’re making healthy possible for Parkinson’s patients.

 

Kyowa Kirin is committed to innovative drug discovery driven by state-of-the-art technologies. We work across the world to champion new solutions for patients and caregivers in four therapeutic areas:  nephrology, oncology, immunology/allergy and neurology (CNS). You can learn more about our values, our business and how we help patients suffering from serious illnesses, like Parkinson’s disease, by visiting https://www.kyowakirin.com.

 

 

Lundbeck, a global pharmaceutical company based in Denmark and founded in 1915, is tirelessly dedicated to restoring brain health, so that every person can be their best. Lundbeck has a long heritage of innovation in neuroscience and is focused on delivering transformative treatments that address unmet needs in brain health.

At Lundbeck, we are motivated by those affected by Parkinson’s disease; they inspire us to make progress to advance treatments and programs that benefit them. We believe that by bringing together patients, care partners, healthcare professionals and advocacy organizations, we can multiply the impact of our efforts and enable real, sustainable improvement in the lives of those affected by Parkinson’s. For more information, visit us at http://www.lundbeck.com/us

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s websites: www.sunovion.com, www.sunovion.eu and www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

Click for a printer friendly version

Back